Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis (PanGen)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02869802 |
Recruitment Status :
Recruiting
First Posted : August 17, 2016
Last Update Posted : August 4, 2023
|
Sponsor:
British Columbia Cancer Agency
Collaborators:
Terry Fox Research Institute
BC Cancer Foundation
Pancreas Centre BC
American Society of Clinical Oncology
Information provided by (Responsible Party):
British Columbia Cancer Agency
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Recruiting |
---|---|
Estimated Primary Completion Date : | December 2023 |
Estimated Study Completion Date : | December 2024 |
Publications of Results:
Other Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Other Publications:
Canadian Cancer Society's Advisory Committee on Cancer Statistics. Canadian Cancer Statistics 2015. Toronto, ON: Canadian Cancer Society; 2015.
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):